Citigroup maintains CRSP (CRISPR Therapeutics AG) at Buy Feb 2026
Citigroup on February 16, 2026 maintained CRSP at Buy and raised the price target to $80 from $77. This CRSP analyst rating update signals confidence in CRISPR Therapeutics AG’s pipeline and value upside potential. We track the change and explain what it means for investors.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
